Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy‐Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial

BACKGROUND: For the prevention of chemotherapy‐induced nausea and vomiting (CINV) during the delayed phase (24–120 hours) after moderately emetogenic chemotherapy (MEC), the use of 3‐day dexamethasone (DEX) is often recommended. This study compared the efficacy and safety of two DEX‐sparing regimens...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: van der Vorst, Maurice J.D.L., Toffoli, Elisa C., Beusink, Marlien, van Linde, Myra E., van Voorthuizen, Theo, Brouwer, Saskia, van Zweeden, Annette A., Vrijaldenhoven, Suzan, Berends, Johan C., Berkhof, Johannes, Verheul, Henk M.W.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Symptom Management and Supportive Care
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794169/
https://ncbi.nlm.nih.gov/pubmed/32735029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0305
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados